Hypertension, high-dose corticosteroids, and renal infiltration in children with acute lymphoblastic leukemia

Juliansen, Andry; Andriastuti, Murti; Pardede, Sudung O.; Sekartini, Rini

doi:10.14238/pi54.6.2014.372-6

Cited by 4 publications

(2 citation statements)

References 12 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study involving acute lymphoblastic leukemia (ALL) children reported that the risk factors for HT include high dose corticosteroids, hyperleukocytosis, tumor lysis syndrome, kidney leukemic infiltration, and sepsis. [21,22] This cross-sectional study showed that 14% of patients with ALL had HT. [23] Other studies reported a higher incidence of HT among children with ALL or lymphoma.…”

Section: Discussionmentioning

confidence: 95%

Antihypertensive management in children: A two-year experience of indonesia’s national referral hospital

Puspitasari¹

2020

Anatol JFM

View full text Add to dashboard Cite

Several factors, including unfavored perinatal events, nutritional status, and comorbidities are Objectives: The prevalence of hypertension (HT) in children has increased overtime. However, data related to antihypertensive options and outcomes are still limited in children, especially in Indonesia. This study aimed to describe pediatric HT cases and antihypertensive management in Cipto Mangunkusumo General Hospital (CMGH). Methods:A retrospective cross-sectional study was conducted in CMGH from January 2016 to December 2017. Inclusion criteria were children age <18 years with primary and secondary HT visiting pediatric nephrology clinic. Patients were excluded if no blood pressure records were found. Clinical and antihypertensive treatments data were recorded from medical records. Diagnosis was based on the Fourth Report classification. Results:This study included 176 children with HT. Secondary HT was found in 159 (90.3%) patients, and 82 (51.6%) of them had isolated kidney-urinary tract disease. Dual antihypertensive therapy was prescribed for 53 (30.1%) patients, whereas 55 (31.3%) patients was monotherapy. The most common antihypertensive used in monotherapy was angiotensin converting enzyme inhibitors (ACEI), received by 31 (56.3%) patients. The median duration of therapy until achievement of target blood pressure was 28.0 (1.0-365.0) days. Conclusion:Pediatric HT is an often overlooked growing medical issue. Secondary HT was found more in children compare to primary HT. Secondary etiology was suspected if HT was found in children with kidney disease. The first-line antihypertensive drug used was ACEI, as single or combination therapy. The therapeutic effect of antihypertensive drugs was expected within 28 days of treatment.

show abstract

Section: Discussionmentioning

confidence: 95%

Antihypertensive management in children: A two-year experience of indonesia’s national referral hospital

Puspitasari¹

2020

Anatol JFM

View full text Add to dashboard Cite

show abstract

“…Glucocorticoids form the backbone of induction and reinduction phases of ALL therapy and hypertension is an important though often under-reported non-hematological toxicity associated with its use. [8][9][10][11][12][13] No study has been conducted on pediatric population in Bangladesh. Through the study, we shall come to know about the incidence and risk factors of hypertension in childhood acute lymphoblastic leukemia which would give more insight into the spectrum of problem and would help to design follow-up plans and in planning treatment in our population.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of hematological and biochemical factors of hypertension during the induction chemotherapy for childhood acute lymphoblastic leukemia

Saha,

Jamal,

Soma

et al. 2023

Int J Contemp Pediatr

View full text Add to dashboard Cite

Background: Acute lymphoblastic leukemia (ALL) is a prevalent childhood cancer, accounting for approximately 25% of all pediatric cancer cases. The incidence of hypertension in ALL patients is significantly higher compared to the general pediatric population, emphasizing the need for a better understanding and management of this condition. The aim of the study was to evaluate hematological and biochemical factors of hypertension during the induction of chemotherapy for childhood ALL. Methods: This prospective observational study was conducted in the Department of Pediatric Hematology and Oncology at BSMMU from July 2017 to June 2018. The study included 93 newly diagnosed cases of ALL in children aged 1 to 17.9 years, excluding those below 1 year and above 18 years, known cases of hypertension, patients with pre-existing hypertension before chemotherapy, and old or relapse cases of ALL. Results: The study found that 17.2% of the study population experienced renal derangement during the induction remission phase, while the majority (82.8%) did not. The presence of renal derangement was not significantly associated with hypertension. However, patients who developed tumor lysis syndrome (TLS) had a higher percentage (12.5%) of hypertension compared to the non-hypertensive group (1.3%). Febrile neutropenia, convulsion, and coagulopathy were also observed in patients who developed hypertension more frequently. The median time to detect hypertension during induction chemotherapy was on day 8, with a mean duration of 13.6 days. Conclusions: In this study, hypertension is observed in 17.2% of patients during induction chemotherapy for ALL with higher frequency in the second week and associations with tumor lysis syndrome, febrile neutropenia, convulsion, and coagulopathy.

show abstract

Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy

et al. 2018

View full text Add to dashboard Cite

Hypertension, high-dose corticosteroids, and renal infiltration in children with acute lymphoblastic leukemia

Cited by 4 publications

References 12 publications

Antihypertensive management in children: A two-year experience of indonesia’s national referral hospital

Antihypertensive management in children: A two-year experience of indonesia’s national referral hospital

Evaluation of hematological and biochemical factors of hypertension during the induction chemotherapy for childhood acute lymphoblastic leukemia

Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy

Contact Info

Product

Resources

About